MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.
In less than a decade, cancer diagnosis and treatment has progressed considerably. As in many other cancers, “histologic historical classification” of lung tumors into sub-types (squamous cell, adenocarcinoma, large or small carcinoma cells) was disrupted by the advent of molecular profiling. Today, more than a dozen forms of lung tumors have been identified based on molecular alterations leading to bio-guided treatments, marketed or under development, with a significant improvement in survival. Furthermore, by unlocking the immune system of patients, new immunotherapy antibodies have allowed spectacular survival rates in some advanced forms of cancer.
At this time, many of these drugs are still in the development phase. The first goal is to facilitate patient access to these new options. In response, we have created two APHM services exclusively dedicated to the early transfer of these innovations. Each year, over 600 patients with metastatic lung cancers access this type of treatments including over 200 in the context of trials investigating new drugs or new strategies, of which almost half currently based on immunotherapies. The second goal is obviously to optimize and accelerate the development of these innovations, particularly immunotherapies. To date, only about 20% patients respond to these treatments. With researchers and industrials, we are seeking ways to identify in advance those responders using biomarkers, understand the mechanisms of resistance to current treatments and test new therapeutic combinations able to circumvent these resistances.
At the interface of the laboratory and the patient’s bed, these projects require expertise and interdisciplinarity, highlighted in the collective Marseille Immunopole. MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.#clinic
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
With MI-mAbs and other cluster platforms, CIPHE is somewhat the "technology back office" of Marseille Immunopole.
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.